INFIQ Stock - Infinity Pharmaceuticals, Inc.
Unlock GoAI Insights for INFIQ
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Revenue | $2.59M | $1.86M | $1.72M | $3.05M |
| Gross Profit | $1.03M | $738,000 | $682,000 | $-4,259,000 |
| Gross Margin | 39.7% | 39.7% | 39.7% | -139.7% |
| Operating Income | $-44,844,000 | $-45,083,000 | $-38,497,000 | $-45,664,000 |
| Net Income | $-44,369,000 | $-45,262,000 | $-40,492,000 | $-47,057,000 |
| Net Margin | -1711.1% | -2436.1% | -2355.6% | -1543.4% |
| EPS | $-0.50 | $-0.53 | $-0.68 | $-0.83 |
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts. On September 29, 2023, Infinity Pharmaceuticals, Inc. along with its affiliate, a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on March 7, 2024.
Visit WebsiteEarnings History & Surprises
INFIQEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 8, 2024 | — | — | — | — |
Q2 2024 | Jun 18, 2024 | — | — | — | — |
Q1 2024 | Feb 2, 2024 | — | — | — | — |
Q4 2023 | Dec 22, 2023 | — | — | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.11 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.12 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.10 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.12 | — | — |
Latest News
Frequently Asked Questions about INFIQ
What is INFIQ's current stock price?
What is the analyst price target for INFIQ?
What sector is Infinity Pharmaceuticals, Inc. in?
What is INFIQ's market cap?
Does INFIQ pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to INFIQ for comparison